In situ size amplification strategy reduces lymphatic clearance for enhanced arthritis therapy DOI Creative Commons

Xianyan Qin,

Luhan Zhang,

Yang‐Bao Miao

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Dec. 18, 2024

Rheumatoid arthritis (RA) is an autoimmune disorder characterized by painful swelling and inflammation, arising from the immune system attacking on healthy cells. However, arthritic sites often experience increased lymph flow, hastening drug clearance potentially reducing treatment effectiveness. To address this challenge, in situ size amplification has been proposed to reduce lymphatic thereby enhance therapy. This developed based a conjugate of dexamethasone (Dex) polysialic acid (PSA), linked via acid-sensitive linker, supplemented with bis-5-hydroxytryptamine (Bis-5HT) PSA backbone. Under physiological conditions, autonomously assembles into stable nanoparticles (PD5NPs), facilitating prolonged circulation targeted delivery inflamed joints. Upon arrival at joints, Bis-5HT reacts elevated myeloperoxidase (MPO) levels oxidative stress, prompting particle aggregation in-situ amplification. nanocarrier effectively reduces serves as reservoirs for sustained Dex release acidic pH environments within sites, thus continuously alleviating RA symptoms. Moreover, investigation underlying mechanism elucidates how influences transportation PD5NPs joints vessels. Our study offers valuable insights optimizing nanomedicine performance vivo augmenting therapeutic efficacy.

Language: Английский

Physicochemical Properties of Carriers for Targeting Lymphatic System DOI
Chukwuebuka Emmanuel Umeyor, Popat Kumbhar, Rashmi Trivedi

et al.

Published: Jan. 1, 2024

Language: Английский

Citations

0
Challenges and Limitations of the Lymphatic Drug Delivery Systems DOI

Zahra Khademi,

Negar Mottaghi-Dastjerdi,

Hamed Morad

et al.

Published: Jan. 1, 2024

Language: Английский

Citations

0
In Situ Size Amplification Strategy Suppresses Lymphatic Clearance for Enhanced Arthritis Therapy DOI Creative Commons

Xianyan Qin,

Luhan Zhang,

Yang‐Bao Miao

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 5, 2024

Abstract Rheumatoid arthritis (RA) is an autoimmune condition causing painful swelling and inflammation due to immune system attacks on healthy cells. However, arthritic sites often experience increased lymph flow, hastening drug clearance potentially reducing treatment effectiveness. To address this challenge, in situ size amplification has been proposed inhibit lymphatic thereby enhance therapy. This developed based a conjugate of dexamethasone (Dex) polysialic acid (PSA), linked via acid-sensitive linker, supplemented with bis-5-hydroxytryptamine (Bis-5HT) the PSA backbone. Under physiological conditions, autonomously assembles into stable nanoparticles (PD5NPs), facilitating prolonged circulation targeted delivery inflamed joints. Upon arrival at joints, Bis-5HT reacts elevated myeloperoxidase (MPO) levels oxidative stress, prompting particle aggregation in-situ amplification. nanocarrier effectively inhibits serves as reservoirs for sustained Dex release acidic pH environments within sites, thus continuously alleviating RA symptoms. Moreover, investigation underlying mechanism elucidates how influences transportation PD5NPs from joints vessels. Our study offers valuable insights optimizing nanomedicine performance vivo augmenting therapeutic efficacy.

Language: Английский

Citations

0
Attapulgite microspheres coated with poly(lactic acid-glycolic acid) nanoparticles form satellite structure to enhance doxorubicin delivery in bone cancer therapy DOI
Yu Wang,

Lisi Yan,

Xu Yan

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 104, P. 106509 - 106509

Published: Dec. 7, 2024

Language: Английский

Citations

0
In situ size amplification strategy reduces lymphatic clearance for enhanced arthritis therapy DOI Creative Commons

Xianyan Qin,

Luhan Zhang,

Yang‐Bao Miao

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Dec. 18, 2024

Rheumatoid arthritis (RA) is an autoimmune disorder characterized by painful swelling and inflammation, arising from the immune system attacking on healthy cells. However, arthritic sites often experience increased lymph flow, hastening drug clearance potentially reducing treatment effectiveness. To address this challenge, in situ size amplification has been proposed to reduce lymphatic thereby enhance therapy. This developed based a conjugate of dexamethasone (Dex) polysialic acid (PSA), linked via acid-sensitive linker, supplemented with bis-5-hydroxytryptamine (Bis-5HT) PSA backbone. Under physiological conditions, autonomously assembles into stable nanoparticles (PD5NPs), facilitating prolonged circulation targeted delivery inflamed joints. Upon arrival at joints, Bis-5HT reacts elevated myeloperoxidase (MPO) levels oxidative stress, prompting particle aggregation in-situ amplification. nanocarrier effectively reduces serves as reservoirs for sustained Dex release acidic pH environments within sites, thus continuously alleviating RA symptoms. Moreover, investigation underlying mechanism elucidates how influences transportation PD5NPs joints vessels. Our study offers valuable insights optimizing nanomedicine performance vivo augmenting therapeutic efficacy.

Language: Английский

Citations

0